RxDoctor Payments Data

Carolyn von Maur

Family Medicine · Portage, MINPI 1023114477

Payments from drug & device makers

$1,321in general payments, 2019–2025

Across 45 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$418
  • Abbott$172
  • Boehringer Ingelheim$142
  • AbbVie$134
  • AstraZeneca$117
  • Pfizer$102
  • plus $235 from 7 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,321 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$26,702
Medicare patients
112
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$41,101
EliquisApixaban24$35,359
MounjaroTirzepatide19$28,838
ZenpepLipase/Protease/Amylase13$21,310
FarxigaDapagliflozin Propanediol16$18,522
JardianceEmpagliflozin11$17,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,771
LinzessLinaclotide22$14,937
Repatha PushtronexEvolocumab13$7,490
Atorvastatin Calcium355$6,188
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$5,845
OxycontinOxycodone Hcl15$4,703
Levothyroxine Sodium228$3,526
Morphine Sulfate ErMorphine Sulfate119$3,463
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$3,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$418$41,10128 claims
PfizerEliquis$102$35,35924 claims
Lilly USA, LLCMounjaro$34$28,83819 claims
AstraZenecaFarxiga$117$18,52216 claims
Boehringer IngelheimJardiance$142$17,29011 claims
GSKTrelegy Ellipta$16$16,77115 claims
AbbVieLinzess$134$14,93722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Portage

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →